Business Description
Biocept Inc
NAICS : 621511
SIC : 8731
ISIN : US09072V4023
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.57 | |||||
Equity-to-Asset | 0.01 | |||||
Debt-to-Equity | 39.97 | |||||
Debt-to-EBITDA | -0.4 | |||||
Piotroski F-Score | 1/9 | |||||
Beneish M-Score | -10.11 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17 | |||||
3-Year EBITDA Growth Rate | 46.5 | |||||
3-Year EPS without NRI Growth Rate | 45 | |||||
3-Year FCF Growth Rate | 58.3 | |||||
3-Year Book Growth Rate | -36.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 61.12 | |||||
14-Day RSI | 54.98 | |||||
6-1 Month Momentum % | 8.97 | |||||
12-1 Month Momentum % | -71.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.81 | |||||
Quick Ratio | 1.7 | |||||
Cash Ratio | 1.35 | |||||
Days Inventory | 28.7 | |||||
Days Sales Outstanding | 2003.03 | |||||
Days Payable | 57.76 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -46.1 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -1055.02 | |||||
Operating Margin % | -2445.28 | |||||
Net Margin % | -2257.23 | |||||
FCF Margin % | -1311.45 | |||||
ROE % | -213.89 | |||||
ROA % | -82.63 | |||||
ROIC % | -156.96 | |||||
ROC (Joel Greenblatt) % | -160.49 | |||||
ROCE % | -99.37 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.16 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Revenue | 3.66 | |||||
EV-to-Forward-Revenue | 0.93 | |||||
EV-to-FCF | -0.27 | |||||
Earnings Yield (Greenblatt) % | -625 | |||||
FCF Yield % | 4.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Biocept Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.328 | ||
EPS (TTM) (€) | -49.041 | ||
Beta | 0 | ||
Volatility % | 63.66 | ||
14-Day RSI | 54.98 | ||
14-Day ATR (€) | 0.000034 | ||
20-Day SMA (€) | 6.8 | ||
12-1 Month Momentum % | -71.9 | ||
52-Week Range (€) | 6.06 - 25.254 | ||
Shares Outstanding (Mil) | 2.63 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Biocept Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Biocept Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Biocept Inc Frequently Asked Questions
What is Biocept Inc(FRA:B00)'s stock price today?
When is next earnings date of Biocept Inc(FRA:B00)?
Does Biocept Inc(FRA:B00) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |